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Simple Summary: Cancer stem cells (CSCs) are cancer cells that possess traits usually attributed to
stem cells. An increase in CSCs can lead to more rapid cancer progression, treatment resistance and
the increased likelihood of recurrence. To promote CSC survival and associated cancer progression,
cancer cells enter into reciprocal crosstalk with the surrounding tissue environment, as well as with
distant metastatic sites. This mechanism of communication relies, in part, on secreted factors, of
which extracellular vesicles (EVs) are thought to have a critical role. This systematic review evaluates
the current knowledge of cancer communication via EVs to alter the microenvironment to increase
the survival and maintenance of CSCs. A total of 16 studies spanning the EV content, pathway
alterations and CSC-targeting treatments provide new insights into how EVs mediate CSC traits and
identify the gaps in our understanding of how modulation of the microenvironment plays a key role.
Abstract: Cancer stem cells (CSCs) have increasingly been shown to be a crucial element of het-
erogenous tumors. Although a relatively small component of the population, they increase the
resistance to treatment and the likelihood of recurrence. In recent years, it has been shown, across
multiple cancer types (e.g., colorectal, breast and prostate), that reciprocal communication between
cancer and the microenvironment exists, which is, in part, facilitated by extracellular vesicles (EVs).
However, the mechanisms of this method of communication and its influence on CSC populations is
less well-understood. Therefore, the aim of this systematic review is to determine the evidence that
supports the role of EVs in the manipulation of the tumor microenvironment to promote the survival
of CSCs. Embase and PubMed were used to identify all studies on the topic, which were screened
using PRISMA guidelines, resulting in the inclusion of 16 studies. These 16 studies reported on the
EV content, pathways altered by EVs and therapeutic targeting of CSC through EV-mediated changes
to the microenvironment. In conclusion, these studies demonstrated the role of EV-facilitated com-
munication in maintaining CSCs via manipulation of the tumor microenvironment, demonstrating
the potential of creating therapeutics to target CSCs. However, further works are needed to fully
understand the targetable mechanisms upon which future therapeutics can be based.
Keywords: extracellular vesicle; exosome; cancer; cancer stem cell; microenvironment; stem
cell; therapeutics
1. Introduction
Cancer is one of the leading causes of death worldwide, second to only cardiovascular
disease. Cancer cases are predicted to continue to rise, from 18.1 million new cases and
9.5 million cancer-related deaths worldwide in 2018 to 29.5 million new cases per year
and the number of cancer-related deaths to 16.4 million by 2040 [1,2]. There is a critical
need to better understand the mechanisms of cancer progression to develop more effective
management strategies.
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1.1. Cancer Stem Cells
Many of the same abilities that define stem cells can be observed to be shared by cancer
stem cells (CSCs), manifesting in the capacity for unlimited self-renewal, the ability to enter
quiescence, increased drug resistance, increased EMT, alteration of the immune response,
alteration of the surrounding microenvironment, increased cell plasticity and increased
proliferation/invasion (Figure 1). These CSC properties lead to an increased capacity
for treatment resistance, immune system evasion/manipulation, invasion, metastasis,
progression and recurrence [3–7].
Cancers 2021, 13, x 2 of 16 
 
 
and the number of cancer-related deaths to 16.4 million by 2040 [1,2]. There is a critical 
need to better understand the mechanisms of cancer progression to develop more effective 
management strategies. 
1.1. Cancer Stem Cells 
Many of the same abilities that define stem cells can be observed to be shared by 
cancer stem cells (CSCs), manifesting in the capacity for unlimited self-renewal, the ability 
to enter quiescence, i creased drug resistance, increased EMT, alteration of the immune 
response, alteration of the surrou ding microenvironment, increased cell plasticity and 
increased proliferation/invasion (Figure 1). These CSC properties lead to an increased ca-
pacity for treatment resistance, immune system evasion/manipulation, invasion, metasta-
sis, progression and recurrence [3–7]. 
 
Figure 1. Summary of cancer stem cell traits. 
Much like stem cells, CSCs depend on their microenvironment niche to assist in their 
development and maintenance. For example, brain tumors can induce a brain tumor-ini-
tiating cell phenotype within a hypoxic niche to increase the resistance to hypoxic and 
acidic stress [8], whereas the stem cells residing in the avascular niche show increased the 
cytokine release, resulting in inflammation. This can even vary within the microenviron-
ment niche itself. For example, within the bone, CSCs on the periphery of the bone mar-
row niche can be mobilized to enter into the circulation, whilst CSCs within the central 
bone marrow regions may be induced into quiescence. This is particularly relevant in can-
cer metastasis, whereby, once residing in the metastatic microenvironment, CSCs may 
need to exhibit different epigenetic and transcriptional signatures for their maintenance, 
modification of the niche and progression to metastases. 
Figure 1. Summary of cancer stem cell traits.
Much like stem cells, CSCs depend on their microenvironment niche to assist in their
development and maintenance. For example, brain tumors ca i duce a brain tumo -
initiating cell phenotyp within a hypoxic niche to increase the resistance to hypoxic a d
acidic stress [8], whereas the stem cells residing i the avascular nich show increase
the cytokine releas , re ulting in inflammation. T is can even vary within the microen-
vir nment niche itself. For example, within t e bo e, CSCs on the periphery of the b e
arrow niche can be mobilized to enter into the circulation, whilst CSCs wit in the central
bone marrow regions may be induced into quiescence. This is particularly relevant in
cancer metastasis, whereby, once residing in the metastatic microenvironment, CSCs may
need to exhibit different epigenetic and transcriptional signatures for their maintenance,
modification of the niche and progression to metastases.
CSCs communicate with surrounding cells by a variety of signaling mechanisms,
allowing the tumor to have reciprocal communication within itself and the surrounding mi-
croenvironment. This communication allows for the manipulation of the surrounding cells
dependent on the current requirements of the cancer. Crosstalk between the surrounding
cells and the cancer can be between many different cell types, altering their activity, pheno-
type and their presence in the CSC niche [9–12]—for example, the conversion of fibroblasts
into cancer-associated fibroblasts (CAFs) or the creation of an immune privileged area.
Cancers 2021, 13, 2435 3 of 16
Despite our existing knowledge of the role of CSCs in cancer initiation and progression,
the full repertoire of the signaling mechanisms used to maintain the CSCs and mediate
these effects remains to be elucidated. More recently, extracellular vesicles (EVs) were
identified as an important part of the mechanism of communication between the cancer
and its microenvironment.
1.2. Extracellular Vesicles
Extracellular vesicles are a class of small membrane-bound organelles with various
functions, such as cell-to-cell communication or as a cellular waste route. EVs are not one
homogenous group; the term encompasses at least three major subsets of vesicle: exosomes,
microvesicles (MVs) and apoptotic bodies. These groupings are determined by either the
physical characteristics of the vesicles (e.g., size) or the process of their biogenesis [11].
1.2.1. Exosomes
Exosomes are the most researched class of EVs, as they are thought to facilitate
cell-to-cell communication. At 30–150 nm, they are the smallest class of EV and have an
endosomal origin. They are formed from the budding of multivesicular bodies to form
intraluminal vesicles (ILV), which are then released as exosomes into the extracellular space
via the fusing of ILVs with the plasma membrane. Biogenesis is achieved either through
ESCRT-dependent or -independent pathways. The exosome content often reflects that
of the parental cell, containing RNA, DNA, lipids and proteins [12]. Interestingly some
components in the exosome cargo can be enriched to many times the concentration found
in the parental cell, suggesting selective exosome cargo loading, a mechanism further
supported by the presence of proteins associated with cellular sorting processes [13]. This
potentially selected exosome cargo has also been shown to be biologically active in the
recipient cells [14].
1.2.2. Microvesicles
Microvesicles (also termed shedding vesicles, ectosomes, shedding bodies and mi-
croparticles), instead of an endosomal origin, originate via direct budding from the plasma
membrane, which, when excised, is released into the surrounding extracellular space. Typi-
cally, microvesicles are thought to span 100 nm to 2000 nm, although, when a cell becomes
cancerous, it can release “oncosomes”, which are classified as MVs yet are much larger, up
to 10,000 nm, due to biogenesis dysregulation [15]. Much like exosomes microvesicles can
contain RNA, DNA, lipids and proteins, as well as whole or parts of cellular organelles [16].
Given the overlap in size, the separation of exosomes and microvesicles is technically
challenging. Therefore, exosomes and microvesicles are often studied as one population
under the collective term of EVs or small vesicles.
1.2.3. Apoptotic Bodies
Apoptotic bodies are created exclusively when a cell undergoes programmed cell
death (apoptosis) and begins to physically break down. As a cell undergoes apoptosis,
it releases apoptotic bodies that are filled with the broken-down contents of the cell.
The plasma membrane directly buds and excises around the contents and immediate
surrounding cytoplasmic fluid, forming an apoptotic body from 500 nm to 5000 nm,
allowing apoptotic bodies to act as a waste route and packaging the internal contents of
the cell for removal. This process means that the apoptotic bodies can be filled with all
components of the cell, including DNA, RNA, lipids, proteins and organelles [17], aiding
the apoptotic clearance and preventing autoimmune diseases, although recent studies are
beginning to explore a possible role for apoptotic bodies in cell-to-cell communication.
1.2.4. Other EVs
Extracellular vesicles are not only are found within animal cells; they are an inherent
feature of all eukaryotes, bacteria and archaea [18]. Interestingly, in bacteria, there is
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evidence of the existence of exosomes in the size range of 30–150 nm. However, bacteria lack
necessary endosomal organelles to create exosomes, yet are still able to make vesicles within
the size range, suggesting potential subpopulations of exosomes within the 30–150-nm
size range.
Prostasomes are extracellular vesicles of 50 nm–400 nm that are released into the semi-
nal fluid by the prostate gland [19]. Similar to other EVs, the membranes of prostasomes
consist of a phospholipid bilayer. However, the prostasomes surface is enriched with lipids
in an organized structure. The main roles of prostasomes are in the survival of sperm cells
in reproduction, either in increasing motility or in protection from the female’s immune
system [20].
1.3. Extracellular Vesicles in Cancer
The communication between the cancer cells and their surrounding environment has
been found to be important for cancer progression. Previously, this was thought to be
achieved via direct cell–cell contact or via soluble intermediaries, until the role of EVs in
cell-to-cell communication emerged. EVs can bind to recipient target cells, resulting in
either a ligand–receptor-mediated response in the target cell or the uptake of the EV into
the recipient cell for processing [19]. EVs entering the recipient cells have the potential
to release biologically active cargos of RNA, DNA, proteins and organelles to trigger a
response in the recipient cell [21,22]. Cancer cell EVs can mediate crosstalk between the
cancer cells and other surrounding nonmalignant cell types, acting alongside direct cell-to-
cell interactions and secreted soluble factors. When exposed to EVs derived from aggressive
cancer cells, the recipient cancer cells gain increased metastatic/invasive potential and
increased the stemness properties or, in the case of nonmalignant stromal cells, an altered
phenotype to become supportive of cancer progression.
As EVs are stable in most extracellular fluids and are subject to minimal degrada-
tion when in the circulation, they provide an effective means of communication between
the tumor and cells located in distant sites of the body. This ability enables cancer cells
to begin a process of early crosstalk with potential metastatic sites, primarily creating
a microenvironment favorable for later metastasizing cancer cells. The distal communi-
cation between cancer and its metastatic sites via EVs may elucidate some aspects of
organotropism found in metastasizing cancers. For example, osteoblasts and brain cells
are targeted by EVs derived from prostate and breast cancers, respectively, causing the
creation of a premetastatic niche [23]. Studies such as Hoshino et al. 2015 hypothesized
a link between organotropism and the EV cargo, such as integrins [24]. However, the
mechanisms that dictate EV targeting are still largely unknown. This same ability of stable
survival within the extracellular space, alongside protection of the internal cargo, makes
them promising for future biomarkers [25].
EVs can target a multitude of cell types, resulting in different responses to the mes-
sages being communicated. For example, endothelial cells targeted by cancer EVs are
reported to increase their vascular permeability, thereby assisting in cancer metastasis
and progression [26], whilst fibroblasts can be transformed by exposure to cancer EVs
into cancer-associated fibroblasts with protumorigenic and proangiogenic effects [27]. EV
communication between cancer cells and the immune system can have both pro- and
antitumor effects. Where antitumor effects occur, there is often a disruption of the im-
mune activity and inflammatory processes, including the impairment of CD8+ lymphocyte
activation and recruitment of regulatory T cells [28,29], promoting a premetastatic niche
formation via immunosuppression [7]. Immune cells, especially those adapted by the
tumor microenvironment, can also release EVs that have a protumor effect [30]. These
“extracellular vesicle-transformed” noncancer cells, of both the immune and stromal com-
partments, can actively modify the cancer microenvironment, increasing tumor progression
and metastasis.
CSCs have a key role in the progression of cancer, acting to increase the growth,
metastasis, chemoresistance and potential future relapse. As CSCs are dependent on the
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microenvironment, which can be modulated by EVs, the mechanisms employed by EVs
may provide important insights into therapeutically targetable mechanisms to clear the
CSCs at tumor sites. This systematic review evaluates the research on EVs in the progression
and alteration of the tumor microenvironment, highlighting the existing findings and gaps
in our knowledge.
2. Results
The use of our search terms in EMBASE and PubMed identified 54 and 35 publications,
respectively. When duplicates were removed (n = 26), this left 53 unique publications.
These 53 studies were screened for eligibility via title and abstract, and 33 were removed,
leaving 20 articles that were evaluated in full. This resulted in the further removal of four
studies, as there was no inclusion of the EV isolation methods, leaving 16 eligible studies
to be included in the review. A detailed diagram of the review process is represented in
Figure 2.
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The publications span from 2013 to 2020, with only one study meeting the eligibility
criteria in 2013, rising to four studies in 2020 (January–July), as seen in Figure 3A. Their
papers were spilt between cancer types, with a concentration around colorectal cancer, as
seen in Figure 3B.
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eligible study, demonstrating a prevalence of studies in the colorectal and breast cancer fields.
The studies were divided into three categories: extracellular vesicle cargo, activated
pathways and CSC-targeted therapeutics. Four studies focused on extracellular vesicle
cargos, eight studies focused on activated pathways and the final four studies focused on
CSC-targeted therapeutics. The studies in each group were assessed on quality, and the
summaries can be found in Supplementary Tables S1–S3.
2.1. Extracellular Vesicle Cargo
In total, there were four original research studies that investigated the internal contents
of EVs and their links to the increasing stemness in cancer [31–34]. All four studies
initially confirmed that treatment with EVs from increasingly aggressive metastatic cell
li es increased th cancer c ll st mness and EMT status, as assessed by typical EMT and
stemness markers.
Two of the four studies used omics-level approaches [31,33] to identify the transcript
levels and protein contents [33]. These studies reported a range of both miRNAs or proteins
enriched within EVs isolated from cells showing greater stem cell attributes or metastatic
potential. Ramteke et al. 2015 identified a range of 160 proteins, including β catenin
enriched within EVs isolated from prostate cancer, whilst Donnarumma et al. 2017 found
only three miRNA significantly enriched breast cancer cell lines (miR-21-5p, miR-378e and
miR-143-3p) [31,33].
The two remaining studies used a more targeted qPCR approach to determine the
levels of long noncoding RNAs (lncRNAs) and miRNAs. Razmkhah et al. 2017 and
Hardin et al. 2018, from EVs extracted from acute myeloid leukemia and anaplastic thyroid
carcinoma, respectively, demonstrated an enrichment of targets miR-21 and lncRNA linc-
ROR in EVs of cell lines showing an increased metastatic potential and stemness. Both
studies also directly analyzed the effects of the EVs on cancer-associated fibroblasts to
determine the potential effects on the microenvironment [31,33], with both papers reporting
a reciprocal signaling mechanism from CSCs to increase CAF transformation [31,33] and
form CAFs to enhance CSC properties [31].
The quality score for the studies determining the effect of EV cargo on the microen-
vironment and their effect on CSC ranged from 0.46 to 0.77 (full breakdown in Table 1).
Hardin et al. 2018 scored highly due to rigorous EV isolation and the evaluation methods
gaining within eight out of eight of these categories. Conversely, despite an in vivo focus,
Donnurumma et al. 2017 had no noted EV characterization methods (isolation methods
were included), which lowered the overall score (Supplementary Table S1).
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Table 1. Quality assessment score summary.
Quality Criteria
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Eight articles studied the alterations in the activation of the cellular pathways due to EV
exposure, identifying five key regulatory pathway targets (summarized in Figure 4) [35–42].
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studies (31–38). The Wnt/β-catenin and Notch pathways featured in the majority (5/8) of the
studies reviewed.
Three studies focused on a single pathway, Wnt/β-catenin [35,40,42]. Pathway activa-
tion was identified by quantification of the protein β-catenin [35,41] or one of its subsequent
downstream elements, such as CD44, CyclinD1, CyclinD3 and C-myc [40]. All three studies
showed t at at least one component of the β catenin pathway was altered, with Mao et al.
2017 demonstrating the changes in additional the protein components when the cancer cell
stemness was increased [40]. Two further studies focused on the notch1/numb signaling
pathway, a β-catenin-related pathway, showing that the inhibition of NOTCH via NUMB
increased the cancer stem cellness [38,42]. The remaining three studies reported EV modu-
lation of the TGF-β [39], NF-kB [37] and protein kinase B [36] pathways, confirming the
increased activation of each pathway and an increase in the markers related to stemness.
Interestingly, the upregulation of TGF-β, NF-kB and protein kinase B by EVs was also
connected to altered immune cell function, confirming that a key element in creating a niche
favorable to CSC survival is in the alteration of the immune response. This was explored
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further by Hwang et al. 2019 and Cheng et al. 2019, who determined the effect of pathway
alterations upon neutrophils from colorectal cancers [35,37]. Hwang elucidated a multistep
process of crosstalk between the stem cells and neutrophils, whereas Cheng found an
increase in tumor-filtrating CD66(+) neutrophils, causing a decreased number of tumor-
infiltrating CD8(+) T cells. Both confirmed that exosomal RNAs have a role in manipulating
the immune system, providing an immunosuppressive tumor microenvironment.
Two of the eight studies also looked at the effects of EVs on pathway activation in
cancer-associated fibroblasts (CAFs), demonstrating that CSC-to-CAF communication acts
as a route to further increase the stemness. The specific role of fibroblast EVs in CSC-to-CAF
communication in colorectal cancer was further confirmed by Liu et al. 2020, demonstrating
EV-mediated reciprocal crosstalk between CSCs and the microenvironment [39].
The quality score between the studies determining the pathway activation by CSC
EVs to increase the stemness properties were reasonably consistent, ranging from 0.46 to
0.69, with an average of 0.61. Universal scores for EV isolation were low at 1 due to the use
of ultracentrifugation alone; however, this was compensated by all the articles that gained
3 or 4 for the EV evaluation, with the exception of Gu et al. 2016 [36]. A full breakdown
can be found in Supplementary Table S2.
2.3. CSC Targeted Therapeutics
The effect of treatments on cancer cell stemness mediated by EVs was investigated in
four studies [43–46]. Three of the four studies began by confirming that the EVs increased
the cancer cell stemness via tumor sphere formation, enhanced metastatic capabilities or
using stemness markers.
Ovatodiolode (OV), a bioactive component of Anisomeles indica, was tested for its
ability to suppress oral squamous cell carcinoma (OSCC) progression [43]. OV was found
to reduce the miR21-5p, STAT3 and mTOR levels in EVs produced by OSCC CSCs, resulting
in re-sensitization of the OSCC cells to cisplatin and the inhibition of the transformation of
the surrounding fibroblasts. Similar is OV Pacritinib, an FDA-approved chemotherapeutic,
was also found to lower the levels of miR21 found in the EVs produced by glioblastoma
cells. This resulted in an increase in PDCD4 expression within the glioblastoma cells and
subsequent increased sensitivity to Temozolomide [44].
An additional FDA-approved drug, the chemotherapeutic Fludarabine, was identified
as inhibiting the cross-communication mediated by EVs between CSCs and the local
microenvironment on breast cancer. Xing et al. 2018 demonstrated that breast cancer cells
expressing low levels of the lncRNA Xist produced EVs enriched in the expression of
miR-502. These EVs triggered the polarization of microglia that resulted in the suppression
of T-cell proliferation through the upregulation of immunosuppressive cytokines [46].
Fludarabine, was found to be lethal to breast cancer cells expressing low levels of Xist,
blocking this EV-mediated mechanism of communication and the subsequent immune
suppression, resulting in a reduction in brain cells [46].
The targeting of EV cargos in the stroma rather than CSCs was also investigated
by Gernapudi et al. 2015., who determined that the natural compound Shikonin drove
pre-adipocytes to release EVs containing high levels of miR-140. When applied to ductal
carcinoma in situ (DISC) cells, miR-140-enriched EVs reduced the Sox9 expression in the
DISC cells and blocked cancer progression [43].
Quality scores for the studies assessing possible treatments to block the EV-mediated
effects on cancer cell stemness and cancer progression ranged from 0.38 to 0.69. Studies
evaluating the FDA-approved drugs scored highly in each assessment criteria due to large
sample sizes and the use of the drug, allowing for human samples and databases to be
included, whilst the lowering scorings studies lacked extensive EV isolation and evaluation
methods. A full breakdown can be found in Supplementary Table S3.
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3. Discussion
3.1. Extracellular Vesicle Cargo
A large proportion of the cell-to-cell communication mediated by the vesicles is
believed to be via the cargo. The EV cargos contain different proteins, lipids, RNAs and
DNAs, which may be representative of the parental cell or show a significant enrichment
of certain molecules. The enrichment of some proteins and RNAs within EVs has been
shown to cause modulation of the microenvironment and premetastatic niche formation,
via increasing the stemness and alteration of surrounding the stromal and immune cells.
The contents of the EVs have become of increasing interest, as others have shown DNA [47],
RNAs [48] and proteins [21] to have a biologically active role after delivery to recipient
cells from EVs.
Four studies determined the contents of the EVs and their effects on cancer stem cells,
finding that either specific RNAs or proteins were enriched in the cargos of EVs produced
by metastatic cancer cells compared to their less malignant counterparts and affected the
CSCs and tumor progression [31–34]. Interestingly, despite the different approaches, two
independent studies found miR-21 to be one of the highest increased cargo components of
cancer cell EVs [31,34]. Although no potential targets or mechanisms of action were deter-
mined in these studies, the targets of miR-21 in tumorigenesis have been well-dissected
within the literature.
miR-21 has been shown to be involved in many pathways, including acting as a
prosurvival factor within antiapoptotic pathways [49,50] across multiple cell types. Specific
targets of miR-21 include the matrix metalloproteinases (MMPs) and intracellular Toll-
like receptors, such as TLR7 or TLR8 [51], suggesting miR-21 involvement within the
extracellular structures and innate immunity. Together, with the evidence from the EVs,
the data suggests that vesicular miR-21 can alter the stemness via the modulation of the
surrounding microenvironment through both matrix and immune cell manipulation.
Ramteke et al. analyzed the protein contents of the EVs from prostate cancer and
found that most of the proteins were involved with either cytoskeleton signaling or in
cell-to-cell junction signaling. This further supports the hypothesis that the EV content
has a key function in creating and maintaining a microenvironmental niche for CSCs.
Additionally, this highlights that, much like in a complex disease model, there may be
many elements of the EV cargo, including proteins and RNA, which cumulatively affect
the stemness properties of the cancer cells and their surrounding microenvironment.
The altered contents of cancer EVs, particularly of some highly enriched components
such as miR-21, has led to the exploration of the use of EVs as biomarkers. The current
diagnostic and prognostic markers for cancer lack either specificity or sensitivity, limiting
their utility. For example, within prostate cancer, the prostate-specific antigen (PSA) is
used as a cancer marker but has a high false-positive rate for diagnosis [52]. EVs have
the potential to replace the current cancer markers and are easily accessible in a range of
biofluids. Although no EV-based biomarkers are currently used for diagnostic or prognostic
purposes, there are multiple studies assessing the clinical use of EVs in cancer, including a
clinical trial of Gylpican-1+ (GPC1+) EVs for the diagnosis of pancreatic cancer [53]. The
topic of the clinical use of EVs as biomarkers has been comprehensively reviewed by
Zhou et al. 2020 [54]. Continued research in this area is likely to yield a range of both
EV-based biomarkers to provide diagnostic and prognostic information.
Taken together, these studies demonstrated that cell-to-cell communication and ma-
nipulation of the microenvironment via stemness is likely, at least in part, to be dependent
upon the cargo of the EVs. Further studying of the functional effects of the EV cargo on
recipient cells may provide the key to understanding the mechanisms mediated by EVs to
affect cancer stem cells.
3.2. Processes Activated by Cancer EVs
The enriched cargo elements of EVs facilitate their ability to communicate between
cells, resulting in increased cancer cell stemness. As the EV cargo is generally biologically
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active when released, the functional studies of EV recipient cells showed a range of altered
pathway signaling and altered gene expression. Eight studies investigated the potential
pathways activated by cancer cell EVs and confirmed an increased stemness that was
directly due to EV exposure.
Three studies focused on a single pathway, Wnt/β-catenin [35,40,42]. All three papers
noted an increased activation of the β catenin pathway, directly causing an increase in
cancer cell stemness. Due to the β-catenin involvement in embryonic development, there
are multiple processes that are thought to contribute to the β-catenins effects, including
mediating cell fate specification, cell cycle progression and cell migration [55]. As well as
modulating the infiltration of other cell types into the tumor microenvironment, such as T
cells [56]. Although β-catenin acts via a range of downstream elements, it is the activation
by transcriptional repressors, such as snail1 and snail2, that appears key to mediating the
CSC properties [56].
Additionally, all three studies linked increased the activation of the target pathway to
a specific biologically active component of the EV cargo. These were miRNAs (miR-146a-5p
and miR-142-3p) [35]; lncRNAs (H19) [41] and proteins (ubr2) [40], with each showing
pathway activation directly correlating with the biological active component. Interestingly,
Ren et al. 2018 found that lncRNA H19 acted as a sponge specifically for miR-141, leading
to increased activation and stemness [41], suggesting that certain miRNAs are vital in
increasing cancer cell stemness via the β-catenin pathway [31,36], alongside the other
cargo components.
In addition to the studies included within this systematic review, other investigations
have found that β-catenin and its downstream elements play a vital role in cancer stem
cell survival in multiple cancer types [57,58] and have a potential function in adapting
metastatic sites such as the bone marrow [59].
Two further studies reported activation of the Notch/Numb pathway. Whilst not indi-
cated in either study, the Notch/Numb signaling pathway is directly linked to β-catenin.
As the notch1 expression is dependent on the β-catenin pathway activation [60], resulting
in five out of the eight papers focused on the codependent pathways of Notch1/Numb and
β-catenin [35,38,40–42]. These findings combined strongly suggest EV-mediated β-catenin
as a critical factor in increasing the CSCs and cancer survival.
Whilst not all of the studies directly investigated the potential of a specific pathway
and activating the component within the EVs cargos, four studies did investigate if exposure
to cancer EVs in general was correlated with the target pathway activation [35,38,40,41].
Even though the pathways were confirmed to be activated by EV exposure, further studies
should be conducted to identify if the EV cargo is responsible for the pathway activation or
if other elements of the process or if EV exposure is responsible for the changes observed,
such as an altered response due to physical contact with the EV or changes in the local
extracellular matrix.
Of note, two studies also investigated the communication from CAFs to CSCs via
the EV cargo elements [39,41]. Each study showed an increase of either TGF-β or the β-
catenin pathway; within both, this resulted in an increase of CSC properties with Ren et al.,
also showing a subsequent increase in resistance to radiotherapy. This data indicates the
presence of reciprocal communication between the surrounding cells in the microenvi-
ronment and the cancer. Which is supported by Sansone et al. 2017 finding the role of
content of CAF-derived microvesicles activating the Notch pathways via miR-221 [61].
Although this was only shown through CAFs, it illustrates the role played by the tumor
microenvironment to maintain and increase the properties of CSCs.
3.3. Treatment
CSCs can increase the resistance to chemotherapy and radiotherapy. As discussed
previously, EVs can increase the stemness of cancer cells to in part mediate the resulting
resistance to therapy. Currently cancer therapeutic agents are non-selective for CSCs [62].
However, the recent studies reviewed in our report indicate the potential for CSC directed
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therapies that target either pathways altered by CSC EVs or by targeting the CSC EV
content directly.
Of the four studies reviewed, three confirmed the ability of EVs to increase CSC
markers and enhance metastatic capabilities [43–46], with two studies investigating the
effect of EVs on resensitization after the development of chemoresistance. OV treatment
of oral squamous carcinoma led to a significant decrease of the loading of key compo-
nents of the EV cargo that were attributed to the transformation of the surround stromal
cells, specifically fibroblasts. These reduced components were primarily those found
increased in cancer EVs such as miR-21 and β-Catenin, all of which had been linked
with CSC activity previously [35,38,40–42]. These OV induced EV changes led to resensi-
tization of tumors to cisplatin, thought to be through the restoration of the pre-cisplatin
treatment microenvironment.
Similarly, Chuang et al., showed glioblastoma gained temozolomide resistance due to
altering the miR-21 content of EV [44]. Delivery of EV miR-21 converted the macrophages
from an M1 to an M2 (protumor) phenotype. The use of Pacritinib reversed this change,
returning macrophages to the M1 phenotype and, subsequently resensitizing the glioblas-
toma to temozolomide.
Together these studies suggest that targeting the activity of EVs, has the potential
to greatly enhance the effectiveness of chemotherapies, even in tumors previously found
to be resistant. Further research is needed to determine if this type of targeting prevents
alterations of the microenvironment stops the development of chemoresistance as well as
providing a mechanism of resensitization.
The final two studies evaluated Shikonin and Fluarabine, both agents were shown
to have anti-breast cancer CSC properties. Shikonin directly targets the communication
between breast cancer cells and preapodocytes via interruption of the miR-140/SOX9
signaling that is facilitated through EVs. This signaling mechanism has been previously
reported to mediate an immune privileged area in both the immediate surrounding en-
vironment and in metastatic niches [63]. Interrupting this communication mechanism
reduced the aggressive cancer phenotype and chemoresistance by reduced stemness and
preventing alterations within the microenvironment.
Of the compounds tested, it is of note that Fludarabine showed an IC50 value for breast
cancer cells ten times lower than the clinical dose used in treating leukemia, for which
the drug originally gained FDA approval [46]. Additionally, Fludarabine was effective
in treating brain metastasis without any noted side effects in vivo. As the two studies
which evaluated approved FDA drugs (Fludarabine and Pacritinib) had access to human
databases, both studies were able to identify lower relapse rates, which can potentially be
linked back to the treatments targeting CSCs [44,46]. Suggesting other chemotherapies may
prove more effective when repurposed against CSCs in different tumor types. In addition,
these studies also indicate there may be the potential to create newer combination therapies
which can target the cancer microenvironment, CSCs and the primary cancer.
4. Materials and Methods
4.1. Sources and Searches
This review was conducted under the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses (PRISMA) guidelines. Publications were searched for using
EMBASE and PubMed and results were up to July 2020 with the search terms (Exosomes
OR extracellular vesicles OR microvesicles OR microparticles OR ectosomes) AND (cancer)
AND (microenvironment) AND (stemness).
4.2. Study Selection
This systematic review was conducted to determine the role of extracellular vesicles
in the development of a microenvironment favorable to cancer stem cells. Studies which
identified one or more of: EV content, EV effect on recipient cells (pathway activation) or
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a therapeutic approach to targeting CSC via mechanisms facilitated by EVs. With only
publications which contained primary research were included.
Publications were included in this review if they met the criteria summarized Table 2.
Table 2. Inclusion and Exclusion criteria used for study selection.
Inclusion Criteria Exclusion Criteria
Research involving the EV contents, EV effects
on recipients or microenvironment AND/OR
therapeutically targeting EV derived
mechanism of CSCs




Articles published in a language other
than English
No specific EV extraction method or protocol
Methodology Focus
4.3. Study Quality Assessment
To assess the quality of each of the publications viewing the role of EVs in CSCs, each
study was assessed on three key components: EV isolation methods, EV characterization
and the samples analyzed. A summary of quality score criteria can be found (Table 1).
The EV isolation methods were graded to merit the quality/purity of the EVs ex-
tracted (n/4). As any studies with no data on isolation methods were removed during
screening, there was no score of 0. A score of 1 applied to unbuffered ultracentrifugation
only, a score of 2 for size exclusion extraction, a score of 3 for any previous isolation by
ultracentrifugation or seize exclusion chromatography followed by bead extraction. Finally,
as there is no gold standard for EV extraction, if one of the previous methods was used
with additional or novel methods to improve purity, a score of 4 was given.
For the characterization of EVs a score of 0 was given if there was no method of
characterizing the quality of the EVs collected. A score of 1 was given if nanoparticle
tracking or dynamic light scatter was used; a score of 2 was given if nanoparticle tracking
was used alongside a western blot or recommended EV markers; a score of 3 was given if
particle tracking was used with electron microscopy. Finally, a score of 4 was given if at
least two of the other methods were used alongside a novel technique (i.e., FACS).
For assessing the quality of the samples used to analyze the role of EVs in CSCs, a
score from 1-5 was used. A score of 1 was given for 2D in vitro models; a score of 2 for 3D
in vitro models; a score of 3 for use of in vivo animal models. A score of 4 was awarded for
the integration of human patient samples or databases in addition to other models. Finally,
a score of 5 was given for the use of both in vivo human samples and databases.
5. Conclusions
There is a growing body of research determining the mechanisms that govern the
interaction between CSCs and their surrounding environment. The recent entry of EVs
into this field has opened new lines of investigation that play a key role in cell-to-cell
communication alongside other more traditionally studied signaling processes. This
review provided an in-depth coverage of the topic in relation to EVs. It is important to
note that the studies for which the main focus is not CSCs did not incorporate by the
methodology applied, these include those by the Lyden group and others. However,
where these studies pertain to the findings of this analysis, the data support our overall
conclusions as indicated in the discussion. Despite recent advances in EV research, there is
often still a focus on the miRNA content of EVs and the use of targeted approaches that
study only a single EV cargo molecule in isolation. Future studies in this area could focus
on the other RNAs that are present and often more predominant in cancer EVs through
the use of global transcriptome methods. As determined within this review, the majority
of research on pathway alternations focuses on the β catenin/NOTCH signaling pathway.
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More in-depth analysis, particularly longitudinal studies that look at the effects of repeated
EV exposure over time, may present other pathways specific for CSC maintenance and
microenvironment manipulation for further investigation. The field currently views the
reciprocal cross talk between CSC and surrounding cell types as an important element of
microenvironment modulation and increasing cancer cell stemness. Notably neutrophils
and CAFs are two elements demonstrated to provide a key role in EV-modulation of the
tumor microenvironment. The inclusion of other critical components such at the ECM or
tumor associated macrophages may provide an interesting future direction to expanded
upon. An analysis of the spatial efficacy of EVs may also prove to be an important factor
when ascertaining their potential to modulate immune and stromal cell function in vivo.
Therapeutically targeting CSCs currently shows promise to treat metastasizing cancer and
reduce recurrence. This review highlights the potential of repurposing two approved cancer
drugs, which may potentially be effective in other cancer types with decreased toxicity due
to the direct targeting of CSCs and their EVs. Additionally, bioactive components of plants
or herbs pose another potential avenue to target CSCs EVs. In conclusion, the field of CSC
interaction with their microenvironment via EV-facilitated communication is a promising
field. As research grows, exploring EV content, and their target pathways, in relation to the
interplay between CSCs and the tumor microenvironment presents additional targets for
improved therapeutic intervention.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/cancers13102435/s1, Table S1: Assessment of studies reporting the content of EVs and
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Assessment of studies reporting CSC EV directed therapeutics.
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